Most Read Articles
Roshini Claire Anthony, 4 days ago

The combined use of piperacillin and tazobactam does not appear to be a suitable alternative to meropenem for patients with bloodstream infections caused by ceftriaxone-resistant Escherichia coli (E. coli) or Klebsiella pneumoniae (K. pneumoniae), according to results of the MERINO* trial.

Tristan Manalac, 19 May 2018
Taking oral antibiotics appears to increase the risk of nephrolithiasis, according to a recent study. Moreover, the risk seems to be compounded for individuals with recent antibiotic exposure and those who were exposed at a younger age.
2 days ago
Patients with inflammatory bowel disease are at increased risk of developing acute myocardial infarction (AMI) or heart failure, although the prevalence of traditional risk factors for such cardiovascular disorders appears to be low, as reported in a recent study.
3 days ago
Early renin-angiotensin-aldosterone system (RAAS) blockade with renin-angiotensin system inhibitors (RASI) leads to better short- and long-term renal outcomes in systemic lupus erythematosus (SLE) patients with antiphospholipid-associated nephropathy (aPLN), according to a study, adding that this renal protective effect is independent of RASI’s antihypertensive and antiproteinuric effects.

Cerebrospinal fluid B cells do not predict multiple sclerosis progression

10 Aug 2017

B cell subtypes in the cerebrospinal fluid (CSF) of multiple sclerosis (MS) patients are not predictors of disease progression, expanded disability status scale (EDSS) progression or conversion to clinical definite MS (CDMS), a recent longitudinal prospective study has shown.

Over a median follow-up period of 7.9 years, CSF samples were extracted from 40 clinically isolated syndrome (CIS), 27 relapsing remitting MS (RRMS), two secondary progressive MS (SPMS) and nine primary progressive MS (PPMS) patients. A control group of 40 patients with other neurological diseases (OND) was included.

Older age at baseline (odds ratio [OR], 1.7; 95 percent CI, 1.0 to 3.0; p=0.041) was the only significant prognostic factor for MS progression after comparing the SPMS and PPMS with the CIS and RRMS patients.

There were no significant associations found for sex (OR, 0.3; 0.0 to 3.8; p=0.380), duration of disease (OR, 1.3; 0.9 to 1.9; p=0.097), CD19+CD138- cells (OR, 0.0; 0.0 to 7.8; p=0.166) or CD19+CD138+ cells (OR, 0.5; 0.0 to 26.3; p=0.736).

Similarly, age at baseline (OR, 1.1; 1.0 to 1.1; p=0.012) was the only significant prognostic factor for EDSS progression. CD19+CD138- (OR, 0.1; 0.0 to 1.2; p=0.077) and CD19+CD138+ (OR, 1.6; 0.4 to 6.7; p=0.531) cells were not significantly correlated.

On the other hand, flow cytometry analysis showed that the majority of B cells in the CSF of MS patients were either CD19+CD138- mature B cells or CD19+CD138+ plasmablasts. At follow-up, the CSF composition of CIS, RRMS and SPMS patients were significantly different from the OND controls (p<0.001). PPMS CSF composition did not significantly differ from OND CSF composition.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 4 days ago

The combined use of piperacillin and tazobactam does not appear to be a suitable alternative to meropenem for patients with bloodstream infections caused by ceftriaxone-resistant Escherichia coli (E. coli) or Klebsiella pneumoniae (K. pneumoniae), according to results of the MERINO* trial.

Tristan Manalac, 19 May 2018
Taking oral antibiotics appears to increase the risk of nephrolithiasis, according to a recent study. Moreover, the risk seems to be compounded for individuals with recent antibiotic exposure and those who were exposed at a younger age.
2 days ago
Patients with inflammatory bowel disease are at increased risk of developing acute myocardial infarction (AMI) or heart failure, although the prevalence of traditional risk factors for such cardiovascular disorders appears to be low, as reported in a recent study.
3 days ago
Early renin-angiotensin-aldosterone system (RAAS) blockade with renin-angiotensin system inhibitors (RASI) leads to better short- and long-term renal outcomes in systemic lupus erythematosus (SLE) patients with antiphospholipid-associated nephropathy (aPLN), according to a study, adding that this renal protective effect is independent of RASI’s antihypertensive and antiproteinuric effects.